Perosphere Technologies Appoints Steve Ward as Executive Vice President & Chief Financial Officer

Industry Leader Strengthens Leadership Team Amid Continued Growth

DANBURY, Conn.–(BUSINESS WIRE)–Perosphere Technologies (Perosphere Technologies Inc.), a private medical technologies company focused on developing next-generation coagulation diagnostics, today announced the appointment of Steve Ward as Executive Vice President and Chief Financial Officer.

Ward brings extensive experience and a proven track record in establishing and growing companies, both in and out of the medical device industry. He is a leader in strategic planning, developing financial systems technology to meet shifting needs, working with venture capital, and more.

“I am very excited to get to work with the dedicated and passionate Perosphere team, which has developed such a game changing coagulation instrument,” Ward said. “I look forward to contributing to the company’s overall goal of advancing the quality of patient care through innovative diagnostic tools. My previous experience supporting companies through commercialization, and establishing financial controls and excellence in operations makes me uniquely suited to help Perosphere scale, expand, and deliver on its mission to create cutting-edge solutions for patients and health care providers.”

Ward comes to Perosphere from serving as the CFO of Viscogliosi Brothers LLC and Viscogliosi Brothers Acquisition Corp. Prior to that position, he also served as the CFO of Paradigm Spine, CFO and Chief Operating Officer of Small Bone Innovations, Vice President of Finance & Administration at ITC, which launched the Hemochron system for warfarin monitoring, and in various capacities with Howmedica Stryker and KPMG. He has both graduate and undergraduate degrees from Fairleigh Dickinson University.

“We are honored to welcome Steve Ward to our expanding executive team as our new Chief Financial Officer,” said Perosphere CEO Sasha H. Bakhru, PhD. “He brings his extensive experience and strategic mindset to Perosphere at a critical juncture as we begin our commercialization efforts, look to expand worldwide, and drive long term value for our stakeholders. We are confident in Steve’s leadership as we pursue making a difference at the bedside with innovative diagnostic tools for patients.”

About Perosphere Technologies

Perosphere Technologies is changing the way decisions are made for patients at risk of bleeding. A private medical technologies company, Perosphere is focused on development and commercialization of its novel PoC (point-of-care) Coagulometer, which informs diagnosis, treatment, and prevention through precision data, made immediately accessible to all. It is the only point-of-care diagnostic tool that effectively and swiftly tests clotting times across drug classes, including DOACs. The fast diagnosis and related appropriate treatment decisions the PoC Coagulometer enables will help establish a new standard of care in hospital emergency departments for patients at risk for bleeding and has the potential to improve efficiency, provide significant cost savings, and better patient outcomes. The PoC Coagulometer has a CE Mark in the EU but is not yet cleared in the US.

For further information, contact us at or +1 (475) 218-4600.


FINN Partners for Perosphere

Laura O’Neill

Vice President

error: Content is protected !!